Remove 2016 Remove Compliance Remove COVID-19 Remove Nursing Homes
article thumbnail

The Cobra Effect & Enforcing Compliance Standards

AIHC

Lessons Learned about Consequences & Incentives Submitted by the AIHC Education Department Introduction The Office of Inspector General has released the new General Compliance Program Guidance or “GCPG” in late 2023. The article states “An example of this was Wells Fargo in 2016.

article thumbnail

The Cobra Effect & Enforcing Compliance Standards

AIHC

Lessons Learned about Consequences & Incentives Submitted by the AIHC Education Department Introduction The Office of Inspector General has released the new General Compliance Program Guidance or “GCPG” in late 2023. The article states “An example of this was Wells Fargo in 2016.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Nursing License Verification: Necessary, But Complex

Provider Trust

Some additional nursing facts include: The U.S. government estimates that >200,000 new RN positions will be created each year from 2016 to 2026. Most healthcare services involve some sort of care by nurses including private practices, primary care clinics, home health, nursing homes, hospices, and more.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2022 – June

SQA

ANVISA published the RDC 702/2022, which repeals some requirements that were instituted to speed market approval of devices needed to treat patients during the height of the COVID-19 pandemic. The Regulations were first issued with immediate effect in 2002 and were later revised in 2016.

FDA 91
article thumbnail

The BFDs – The Ten Best Prescription Drug/Medical Device Decisions of 2023

Drug & Device Law

While these five FDA findings (the last in response to the MDL court’s invitation for the FDA to participate directly in this litigation) were nails in these experts’ Rule 702 coffins, they would also support reversing this MDL’s prior adverse preemption decision ( 2016-10 ). The G/N MDL was created in 2013 and mostly settled in 2016.

FDA 105